Carbapenem-based Antibiotics Global Market Report 2024

The carbapenem-based antibiotics market size has grown strongly in recent years. It will grow from $4.43 billion in 2023 to $4.66 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth observed in the historic period can be attributed to factors such as the occurrence of epidemics and pandemics, an increase in chronic diseases, expansion of healthcare infrastructure, rapid urbanization, and the impact of natural disasters and health emergencies.

The carbapenem-based antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.71 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period is driven by factors such as the increased incidence of hospital-acquired infections, the emergence of multi-drug resistant strains, a growing aging population, a rise in surgical procedures, the proliferation of infectious diseases, and changing demographics. Major trends expected in the forecast period include a focus on supply chain resilience and security, the development of alternative treatment options, a shift towards outpatient settings, a growing awareness of antimicrobial stewardship, and the adoption of precision medicine approaches.

The projected rise in carbapenem-based antibiotics market growth is attributed to the escalating incidence of bacterial infections. These infections, caused by microscopic organisms known as bacteria, lead to various diseases and symptoms. Carbapenem-based antibiotics are specifically designed to address severe or multidrug-resistant bacterial infections, encompassing both gram-positive and gram-negative bacteria. For instance, as reported by the UK Health Security Agency (UKHSA) in November 2022, there was a 2.2% increase in anticipated total antibiotic-resistant severe infections in 2021. Hence, the surge in bacterial infections is a key driver propelling the growth of the carbapenem-based antibiotics market.

The expansion of the carbapenem-based antibiotics market is anticipated due to the rising number of surgical procedures performed. Surgical procedures encompass a range of medical interventions carried out by qualified surgeons to address diseases, injuries, or conditions affecting different body parts. Carbapenems exhibit a wide spectrum of activity, effectively combating infections within the abdominal cavity, reducing the necessity for combination therapy, simplifying treatment protocols for surgical patients, and proving efficacious in meningitis treatment. For instance, data from the American Society for Metabolic and Bariatric Surgery (ASMBS) in June 2022 revealed that approximately 262,893 bariatric surgeries were conducted in 2021. Therefore, the escalation in surgical procedures directly contributes to the growth of the carbapenem-based antibiotics market.

The prevailing trend driving the carbapenem-based antibiotics market is the emphasis on product innovations. Major industry players within this market segment are actively engaged in innovating their product lines as a strategic approach to maintain their market positions. For example, in September 2021, BDR Pharmaceuticals International Pvt. Ltd., an India-based pharmaceutical company, introduced biapenem into the market. Biapenem is specifically designed for individuals afflicted with lower respiratory infections, complex urinary tract infections, or intra-abdominal infections. Clinical studies have showcased that Biapenem exhibits both clinical and bacteriological efficacy comparable to imipenem/cilastatin in treating patients affected by these ailments.

Leading companies operating in the carbapenem-based antibiotics market are directing their focus towards investments to augment their market revenues. A case in point is Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, which, in June 2021, allocated $40 million in investment toward Spero Therapeutics Inc. This investment granted Pfizer the rights to develop, produce, and market SPR206 outside of the United States and Asia. This financial arrangement is expected to bolster the ongoing clinical advancement of SPR720 and SPR206, providing Spero with substantial financial flexibility and capital. Pfizer's investment aligns with its strategic objective of fostering pioneering research and meeting patient needs, while concurrently empowering Spero to advance clinical development and expand global access to their products. Spero Therapeutics Inc., a US-based biopharmaceutical company dedicated to creating novel therapies for bacterial infections, stands to benefit significantly from this collaboration.

In September 2022, GSK PLC, a pharmaceutical and biotechnology company based in the UK, and Spero Therapeutics, Inc. entered into an exclusive license agreement. The agreement involved an upfront payment of $66 million, with the potential for future milestone payments and tiered royalties. This exclusive license granted GSK the commercialization rights for tebipenem HBr in all regions except for Japan and certain other Asian countries. Spero Therapeutics, a US-based clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments and medicines for bacterial infections, including multi-drug resistant and rare diseases, particularly in the realm of carbapenem oral antibiotics.

Major companies operating in the carbapenem-based antibiotics market report are Pfizer Inc., Merck & Co. Inc., Saint-Gobain S.A., Fresenius Kabi LLC, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca PLC, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Amedica Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics PLC, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation.

North America was the largest region in the Carbapenem-Based Antibiotics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the carbapenem-based antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of carbapenem-based antibiotics include meropenem, imipenem, doripenem, tebipenem, and others. Meropenem, for instance, is a broad-spectrum antibiotic that works by inhibiting bacterial cell wall synthesis, making it effective against a wide range of bacterial infections. It is employed in the treatment of serious bacterial infections such as pneumonia, meningitis, intra-abdominal infections, urinary tract infections, and skin and soft tissue infections. Carbapenem-based antibiotics find application in treating various conditions, including intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin and skin structure infections, acute pelvic infections, prophylaxis of surgical site infection, respiratory tract infections, and gynecologic infections. These antibiotics are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The carbapenem-based antibiotics market research report is one of a series of new reports that provides carbapenem-based antibiotics market statistics, including the carbapenem-based antibiotics industry's global market size, regional shares, competitors with a carbapenem-based antibiotics market share, detailed carbapenem-based antibiotics market segments, market trends, and opportunities, and any further data you may need to thrive in the carbapenem-based antibiotics industry. This carbapenem-based antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carbapenem-based antibiotics market consists of sales of imipenem-cilastatin, meropenem, ertapenem, doripenem, biapenem, panipenem, tebipenem, razupenem, tomopenem, and faropenem. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.


The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.